Slc6a11-CreERT2

Nomenclature

C57BL/6Smoc-Slc6a11em1(CreERT2-polyA(SV40)Smoc

Cat. NO.

NM-KI-200130

Strain State

Sperm cryopreservation

Export PDF

Gene Summary

Gene Symbol
Slc6a11

Synonyms

GAT4; Gat3; Gabt4; D930045G19Rik; E130202I16Rik

NCBI ID

243616

MGI ID

95630

Ensembl ID

ENSMUSG00000030307

Pubmed

Slc6a11

Human Ortholog

SLC6A11

Model Description

A CreERT2-polyA expression cassette was knocked into the Slc6a11 gene start codon site. Slc6a11 encodes GAT3 (Gabt4), a sodium-dependent transporter that uptakes the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which ends the GABA neurotransmission. When Slc6a11-CreERT2 mice are bred with mice containing loxP-flanked sequence, tamoxifen-inducible, Cre-mediated recombination will result in deletion of the floxed sequences in SLC6A11positive cells. Defects in Slc6a11 may result in epilepsy or behavioral and intellectual defects.
Research Application：Cre recombinase tool; Neuroscience

Validation Data

image.png

Fig.1 CreERT2-mediated recombination in the cerebral cortex of Slc6a11-CreERT2; Rosa26-tdTomato mice after tamoxifen treatment.

image.png

Fig. 2 CreERT2-mediated recombination in the cerebral ganglion of Slc6a11-CreER; Rosa26-tdTomato mice after tamoxifen treatment.

image.png

Fig3 Labeling was also observed in pituitary, retina, individual cells of submaxillary gland, large intestine and brown fat, but not in lung, liver, stomach, kidney, pancreas, small intestine, epidermis, cardiac muscle, testis, skeletal muscle, and heart valves（For more information please contact: 400-728-0660.）


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop：Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more